RecruitingPhase 2NCT06967558

The Role of Islet GLP-1 in the Pathogenesis of Prediabetes

Sponsor

Mayo Clinic

Enrollment

60 participants

Start Date

Nov 1, 2025

Study Type

INTERVENTIONAL

Conditions

Prediabetes

Summary

We recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets. However, its regulation is at present unknown. At present it is unknown if these abnormalities develop in prediabetes and whether they contribute to the phenotypes observed. In this experiment we will use blockade of GLP1R to probe the contribution of endogenous GLP-1 secretion to the regulation of fasting glucose and islet function in prediabetes.

Eligibility

Min Age: 25 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Exendin 9-39 and a biological treatment called Saline for people with prediabetes. The study is currently recruiting participants at 1 location. People eligible for this study include aged 25 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.